Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in ItalyPaolo Bidoli, Angelo Delmonte, Rita Chiari et al.|Annals of Oncology|2016Cited by 19
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT AnalysisChristine M. Bestvina, Javier Baena, Balázs Halmos et al.|JTO Clinical and Research Reports|2022Cited by 18
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Nicola Normanno, Raffaella Pasquale et al.|Cancers|2019Cited by 10
P3.02c-094 Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain MetastasesDiego Cortinovis, Francesco Cognetti, Angelo Delmonte et al.|Journal of Thoracic Oncology|2017Cited by 8